- Home
- BODI vs ALLK Comparison
BODI vs ALLK Comparison
Compare BODI & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BODI
- ALLK
- Stock Information
- Founded
- BODI 1998
- ALLK 2012
- Country
- BODI United States
- ALLK United States
- Employees
- BODI N/A
- ALLK N/A
- Industry
- BODI Industrial Machinery/Components
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- BODI Industrials
- ALLK Health Care
- Exchange
- BODI Nasdaq
- ALLK Nasdaq
- Market Cap
- BODI 28.3M
- ALLK 29.5M
- IPO Year
- BODI N/A
- ALLK 2018
- Fundamental
- Price
- BODI $4.71
- ALLK $0.33
- Analyst Decision
- BODI Strong Buy
- ALLK Hold
- Analyst Count
- BODI 3
- ALLK 3
- Target Price
- BODI $10.67
- ALLK $2.00
- AVG Volume (30 Days)
- BODI 23.1K
- ALLK 546.6K
- Earning Date
- BODI 05-14-2025
- ALLK 05-27-2025
- Dividend Yield
- BODI N/A
- ALLK N/A
- EPS Growth
- BODI N/A
- ALLK N/A
- EPS
- BODI N/A
- ALLK N/A
- Revenue
- BODI $418,796,000.00
- ALLK N/A
- Revenue This Year
- BODI N/A
- ALLK N/A
- Revenue Next Year
- BODI N/A
- ALLK N/A
- P/E Ratio
- BODI N/A
- ALLK N/A
- Revenue Growth
- BODI N/A
- ALLK N/A
- 52 Week Low
- BODI $3.70
- ALLK $0.22
- 52 Week High
- BODI $9.90
- ALLK $1.56
- Technical
- Relative Strength Index (RSI)
- BODI 47.11
- ALLK 61.39
- Support Level
- BODI $3.79
- ALLK $0.32
- Resistance Level
- BODI $5.36
- ALLK $0.33
- Average True Range (ATR)
- BODI 0.40
- ALLK 0.00
- MACD
- BODI 0.19
- ALLK -0.00
- Stochastic Oscillator
- BODI 57.39
- ALLK 91.00
About BODI The Beachbody Company Inc. Class A Common Stock
The Beachbody Co Inc is a health and wellness platform providing fitness, nutrition and stress-reducing programs to its customers. The product offerings of the company include Digital Subscriptions, Nutritional Products, and Connected Fitness Products. It earns the majority of its revenue from the United States. The company operates and manages its business in one operating segment. Majority of revenue is through Digital.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.